Navigation Links
Genedata Launches Data Science Services for Precision Medicine
Date:1/19/2017

Genedata, a leading provider of advanced software solutions for pharmaceutical research and development (R&D), today announced the launch of Data Science Services, offering on-demand, project-based expertise in omic data analysis and interpretation for the rapidly evolving field of precision medicine.

Data Science Services allows pharmaceutical R&D organizations to quickly derive scientifically- and commercially-critical conclusions from their omics-based patient profiling projects, without having to invest in software infrastructure or data analysis resources. Extensive experience of 20 years working with leading R&D organizations and the world’s top biopharmaceutical companies, coupled with the industry-leading Genedata Profiler™ platform, ensures that data science projects are executed efficiently and cost-effectively. Data Science Services clients will benefit from the transparent reporting of actionable results, enabling informed decision-making for biopharmaceutical R&D.

Genedata recognized that many companies need sophisticated analyses of their omic data in their precision medicine projects. To meet this need, Genedata has extended its business model to offer access to its scientific expertise via Data Science Services. Genedata’s experienced team of Ph.D. level biologists, bioinformaticians, and statisticians now offers in-depth analyses of omic data in close collaboration with scientists from client organizations.

Data Science Services helps pharma, biotech and other organizations to integrate and analyze complex and challenging omics-related projects such as mode-of-action, large-scale genotyping, pharmacogenomics, patient stratification, and biomarker discovery studies. The service offers detailed analyses and scientifically founded results interpretation of data from next-generation sequencing, microarray, real time-PCR, and other genomic technologies, as well as other omics such as proteomics and metabolomics, in conjunction with clinical and phenotypic data. Data Science Services scientists are experienced in a range of therapeutic areas including oncology, cardiovascular medicine, neurology and diabetes.

Powered by the Genedata Profiler enterprise software platform, which is used by many research organizations for translational and clinical research, Data Science Services provides organizations with comprehensive, actionable analyses that range from the initial planning and experimental design, through pre-processing and data curation, to statistical analysis and scientific interpretation of the results.

As needed, Genedata can also grant access for scientists at client organizations to the Genedata Profiler platform during the project to enable efficient and effective scientific collaboration while ensuring compliance with data privacy (such as HIPAA and EU GDPR), data standards (including CDISC), and GxP regulations.

“With our Data Science Services offering, we offer a full continuum of high quality, science-focused data analysis capabilities,” commented Dr. Othmar Pfannes, CEO of Genedata. “This continuum gives organizations great flexibility to scale their omic data analysis, maximize the value of their investment in data generation, and overcome operational bottlenecks. Clients can choose to take advantage of Data Science Services without investing directly in software infrastructure.”

About Genedata
Genedata transforms life science data into intelligence with a portfolio of advanced software solutions and scientific consulting. With award-winning platforms, combined with deep domain expertise, Genedata enables dramatic increases in productivity and quality of research, development, and production. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, Japan, and the US.

http://www.genedata.com
Follow Us on LinkedIn

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/2017/01/prweb13996652.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Genedata Partners with Crescendo Biologics on Next-generation Immuno-oncology and ADC Programs
2. F-star Selects Genedata Biologics for Immuno-Oncology Therapeutics Discovery
3. Genedata Expands Partnership with MorphoSys to Support New Antibody Libraries and Developability Assessment
4. Genedata Announces the Release of Genedata Bioprocess - New Workflow Platform for Biopharmaceutical Development
5. New Genedata Profiler Release Strengthens Data Security and Patient Privacy in Translational Research
6. Genedata Expressionist® Boosts Speed and Accuracy of Biotherapeutics Characterization
7. Boehringer Ingelheim Chooses Genedata Selector(TM) for Cell Line Development and Cell Culture Optimization
8. Genedata Announces ONO PHARMACEUTICAL Transforms High-Throughput Screening with Genedata Screener
9. Genedata Screener with New SPR, DMPK, HT-Flow and HT-Electrophysiology Support to Showcase at SLAS2016
10. Genedata Announces AstraZeneca Standardizes on Genedata Screener as it Global Screening Platform
11. Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2018)... ... August 21, 2018 , ... ... specializing in medical device compliance and commercialization, has just released a new ... Written and presented by Dr. Mario Kossmann, ESEP at the 28th Annual ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS Bioanalytical ... announce the expansion of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as ... large molecule LC-MS/MS group that will specialize in developing quantitative LC-MS/MS assays for ...
(Date:8/14/2018)... ... 13, 2018 , ... Labconco Corporation manufactures laboratory equipment, specializing ... addition, Labconco produces other lab equipment, such as glassware washers and freeze dryers. ... consistency in design and manufacturing. , Through this webinar, which is sponsored ...
(Date:8/11/2018)... ... ... Researchers performing pressurized NMR or EPR experiments face a danger of the tube ... & EPR by Wilmad-LabGlass – SP Scienceware shields researchers from flying debris and ... significantly grown in popularity over the last several years. As a result, the risk ...
Breaking Biology Technology:
(Date:8/23/2018)... , ... August 21, 2018 , ... ... genomes of diverse cell types and species for the robust functional interrogation of ... for the development of T-cell based immunotherapies, the study of the autoimmunity, the ...
(Date:8/21/2018)... ... August 20, 2018 , ... ... are many challenges to consider. Designers must ensure what is designed can be ... will explore some best practices in flow path design with specific focus on ...
(Date:8/17/2018)... DENVILLE, N.J. and LIEGE, Belgium (PRWEB) , ... ... ... Diagenode today announced the acquisition of NXT-Dx, an established epigenetics service ... epigenetics services including a number of targeted DNA methylation assays using pyrosequencing ...
Breaking Biology News(10 mins):